Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Mifepristone as a therapeutic agent in psychiatry.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2013 Jun;51(6):11-4. Review.

PMID:
23814820
2.

Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.

Gallagher P, Watson S, Elizabeth Dye C, Young AH, Nicol Ferrier I.

J Psychiatr Res. 2008 Oct;42(12):1037-41. doi: 10.1016/j.jpsychires.2007.12.005. Epub 2008 Feb 5.

PMID:
18255098
3.

Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.

Mattsson C, Reynolds RM, Simonyte K, Olsson T, Walker BR.

J Clin Endocrinol Metab. 2009 Apr;94(4):1347-52. doi: 10.1210/jc.2008-2054. Epub 2009 Jan 13.

PMID:
19141586
4.

Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression.

Schatzberg AF.

World J Biol Psychiatry. 2015 Jan;16(1):2-11. doi: 10.3109/15622975.2014.916414. Epub 2014 Jun 16. Review.

PMID:
24933348
5.

HPA axis alterations in mental disorders: impact on memory and its relevance for therapeutic interventions.

Wingenfeld K, Wolf OT.

CNS Neurosci Ther. 2011 Dec;17(6):714-22. doi: 10.1111/j.1755-5949.2010.00207.x. Epub 2010 Dec 8. Review.

PMID:
21143429
6.

Is mifepristone useful in psychotic depression?

Carroll BJ, Rubin RT.

Neuropsychopharmacology. 2006 Dec;31(12):2793-4; author reply 2795-7. No abstract available.

7.

Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.

Gross C, Blasey CM, Roe RL, Belanoff JK.

Obesity (Silver Spring). 2010 Dec;18(12):2295-300. doi: 10.1038/oby.2010.51. Epub 2010 Mar 25.

8.

Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.

Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN.

Aust N Z J Psychiatry. 2007 Apr;41(4):321-6.

PMID:
17464718
9.

Antiglucocoticoid treatments for depression.

Young AH.

Aust N Z J Psychiatry. 2006 May;40(5):402-5. Review.

PMID:
16683965
10.

The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa.

Bou Khalil R, Souaiby L, Farès N.

Physiol Behav. 2017 Mar 15;171:13-20. doi: 10.1016/j.physbeh.2016.12.035. Epub 2016 Dec 30. Review.

PMID:
28043861
11.

Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders.

Martocchia A, Curto M, Toussan L, Stefanelli M, Falaschi P.

Recent Pat CNS Drug Discov. 2011 Sep 1;6(3):196-204. Review.

PMID:
21834781
12.

[The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].

Ströhle A.

Nervenarzt. 2003 Mar;74(3):279-91; quiz 292. German.

PMID:
12627245
13.

Effects of psychotropic medications on hypothalamic-pituitary-adrenal regulation.

Meador-Woodruff JH, Greden JF.

Neurol Clin. 1988 Feb;6(1):225-34. Review.

PMID:
2898096
14.

[Stress and psychotic transition: A literature review].

Chaumette B, Kebir O, Mam Lam Fook C, Bourgin J, Godsil BP, Gaillard R, Jay TM, Krebs MO.

Encephale. 2016 Aug;42(4):367-73. doi: 10.1016/j.encep.2015.10.001. Epub 2016 May 6. Review. French.

PMID:
27161263
15.

Stress responsive neurohormones in depression and anxiety.

Ströhle A, Holsboer F.

Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S207-14. Review.

PMID:
14677081
16.

The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression.

Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams GH, Kraemer FB, Schatzberg AF.

Psychoneuroendocrinology. 2013 Jan;38(1):115-21. doi: 10.1016/j.psyneuen.2012.05.006. Epub 2012 Jun 21.

17.

Hypothalamic-pituitary-adrenal axis and bipolar disorder.

Daban C, Vieta E, Mackin P, Young AH.

Psychiatr Clin North Am. 2005 Jun;28(2):469-80. Review.

PMID:
15826743
18.

Disturbances of the stress response: the role of the HPA axis during alcohol withdrawal and abstinence.

Adinoff B, Iranmanesh A, Veldhuis J, Fisher L.

Alcohol Health Res World. 1998;22(1):67-72. Review.

PMID:
15706736
19.

Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia.

Walker E, Mittal V, Tessner K.

Annu Rev Clin Psychol. 2008;4:189-216. doi: 10.1146/annurev.clinpsy.4.022007.141248. Review.

PMID:
18370616
20.

Targets of anti-glucocorticoid therapy for stress-related diseases.

Martocchia A, Stefanelli M, Falaschi GM, Toussan L, Rocchietti March M, Raja S, Romano G, Falaschi P.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):79-87. Review.

PMID:
23489288

Supplemental Content

Support Center